Europe’s Most Advanced Weather Satellite Is Now Fully Operational
4.12.2024 15:26:00 EET | Business Wire | Press release
The first of EUMETSAT’s Meteosat Third Generation (MTG) satellites became fully operational today.
MTG-Imager 1 also receives a new name – Meteosat-12 – to mark the occasion.
The two main instruments on board Meteosat-12, the Flexible Combined Imager (FCI) and the Lightning Imager (LI), play a crucial role in enabling meteorological services to help protect lives and livelihoods by providing high-resolution, accurate data for predicting severe weather events.
Data from Meteosat-12’s instruments are now being disseminated to national meteorological services and others for operational use and are expected to have a significant impact on weather forecasting and understanding of our climate.
“MTG is one of the most innovative and complex meteorological satellite systems ever built,” EUMETSAT Director-General Phil Evans said.
“We have been working with our member states’ meteorological services to ensure they can make the best use of the data, which is essential for one of the main challenges they face - the rapid detection and forecasting of severe weather so that citizenry, civil authorities and first responders receive timely warnings.”
“When the full constellation of MTG is in place, it will be possible, for the first time, to observe the full lifecycle of a convective storm, from before clouds begin to form through to detection of lightning strikes.”
Efficient and impactful use of this new data will also be central to the EU-funded Space for Early Warnings in Africa project, implemented with the African Union Commission. Today, Council approved EUMETSAT’s involvement via an agreement with the European Commission. Starting in January 2025, the project will enhance African capacity to access and process Earth observation data, strengthening early warning systems and resilience to severe weather.
In addition to the FCI and LI, Meteosat-12 also carries the Data Collection and Retransmission Service (DCS) and the Geostationary Search and Rescue Relay (GEOSAR) transponder.
The DCS acquires observations and environmental data from ground-based meteorological platforms in its field of view then transmits them to the MTG ground segment. The GEOSAR transponder acquires signals from distress beacons in its field of view and transmits them to rescue services.
An anomaly in a module of the Flexible Combined Imager meant its commissioning phase lasted longer than anticipated when the spacecraft was launched in mid-December 2022.
“A great deal of hard work, dedication and ingenuity went in to overcoming the anomaly while the satellite was already in orbit 36,000km above the Earth,” Evans said. “I pay tribute to the EUMETSAT teams, supported by ESA and the industry, that achieved that feat and enabled us to reach this important milestone today where we are confident of the quality and reliability of the data we are providing to those who need it.”
Note to editors:
- live imagery from Meteosat-12 is available on the EUMETSAT website: https://www.eumetsat.int/real-time-imagery/earth-view
- Media kit: UNDER EMBARGO UNTIL 04.12.2024 AT 13h15 - METEOSAT 12 becomes operational | Trello
About EUMETSAT
EUMETSAT, Europe’s meteorological satellite agency, monitors the weather and climate from space. Based in Darmstadt, Germany, EUMETSAT provides its 30 member states with meteorological imagery and data that are essential for keeping their communities safe and for the benefit of critical sectors of their economies.
EUMETSAT’s 30 member states are: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.
For more information, see the EUMETSAT website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204449728/en/
Contacts
Media Relations EUMETSAT:
Tel: +49 6151 807 7320
Email: press@eumetsat.int
www.eumetsat.int -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eumetsat.in
t&esheet=54161656&newsitemid=20241204449728&lan=en-US&anchor=www.eumetsat.int&in
dex=3&md5=b5658ad5621c92013fc6ca7c401f9364
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom